Thursday, October 15, 2026

Data Center Power Demand to Rise 165% by 2030, Straining a Grid Built for 1% Annual Growth

Goldman Sachs projects data center electricity consumption will surge 165% by 2030, driven by AI workloads that consume 10x more energy per query than traditional search. The US grid, designed for 1-2% annual demand growth, faces structural scarcity — creating durable pricing power for utilities near major AI data center corridors.

LM Salvado
LM Salvado

June 23, 2026

Data Center Power Demand to Rise 165% by 2030, Straining a Grid Built for 1% Annual Growth
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Data center electricity demand will rise 165% by 2030, according to Goldman Sachs research.1 That single projection is restructuring how institutional investors value US utility and grid infrastructure stocks.

The driver is AI compute. A single ChatGPT query consumes roughly 10 times the energy of a Google search.2 Training next-generation large language models requires power equivalent to small cities.2

Microsoft, Amazon, and Alphabet are among the largest consumers on the US electricity grid.2 Their data center energy demand is structurally price-inelastic — compute must run regardless of power costs. That dynamic is fundamentally different from residential or commercial electricity demand, which responds to price signals.

The US grid was engineered for 1-2% annual demand growth.2 That design assumption is now a binding constraint. Existing grid-connected generation capacity near major data center hubs carries scarcity value that utilities did not price into long-term planning.

Power purchase agreements (PPAs) with AI hyperscalers are emerging as the key earnings quality metric for utility investors. Utilities that executed long-term supply contracts before the AI demand surge — particularly those with generation assets near Northern Virginia, Phoenix, Chicago, and Dallas data center corridors — carry the strongest forward earnings visibility.

Bitzero Holdings (AIBZ) is among the companies targeting this infrastructure intersection.2 The investment thesis: proximity to AI workload demand creates a recurring, durable revenue base that traditional industrial or residential customers cannot replicate.

Capacity factor utilization is the operational signal to watch. Grid-connected generation near high-density compute clusters runs at higher utilization rates, compressing unit economics and improving asset returns over time.

The primary risk is regulatory lag. US utility rate structures were not designed for large industrial AI customers. Interconnection queues and cost-allocation frameworks are under review in multiple states as grid strain increases — adding permitting uncertainty to new capacity build-out timelines.

Goldman Sachs projects 165% data center power demand growth through 2030.1 That implies a structural shift in who the marginal electricity buyer is. Utilities near established AI infrastructure corridors, with contracted supply agreements in place, are the direct beneficiaries of that shift.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com